(2026). Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. Breast Cancer : Targets and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor Versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer."
Breast Cancer : Targets and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor Versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer."
Breast Cancer : Targets and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.